Remnant Cholesterol, triglycerides and cardiovascular risk
GLP 1RA Gate to the future
Case presentation
Advances of basal insulin
Clinical Case
Diabetes and COVID 19
Case presentation
Subclinical thyroid disorders
Prevention of amputation in diabetic patient
Updates on T2DM Management Where Would Sitagliptin Fit in the
SGLT2 inhibitors; a Step Forward in the Management of Type 2 Diabetes
Special types of Diabetes
Case presentation
Remnant Cholesterol, triglycerides and cardiovascular risk 1
Rage Beyond the usual
Picking the right tool in atherosclerosis case study
PCSK9 inhibition and cardiovascular disease prevention
Comprehensive T2D management from glucocenteic to holistic approach
B right from the start
Dapagliflozin, beyond glycemic control
Panhypopituitarism
Congenital hypothyroidism and nephrocalcinosis Is there a link
Approach to thyroid nodule
Workshop of hirsutism Recent guidelines
Evidence based use of glucocorticoids in thyroid practice
Topic How to apply the recent Diabetes Guidelines with focus on Dapagliflozin
Topic Rosuvastatin Ezetimibe combination in management of Diabetic
Cognitive Impairment in diabetes .
Diabetes management in the era of cv outcome trials
The challenging of a Diabetes Patient in Primary care
Individualization of therapy in T2DM in patients with CKD
Fats of Life the Skinny on What’s Coming
Insulin and glucose cotransporter
C peptide, The new player
Industrial Symposium MERK
New onset post transplant diabetes .
Empagliflozin and Cardio Renal Protection
Introducing soliqua Iglarlixi
OADs, the best of both worlds
Co formulation the new generation of insulin combination
Liraglutide 3 0mg filling the gap in obesity management
Diabetes in the youth
Estrogen as a cardioprotective